HEMO BIOENGINEERING LTD

HeMo is a fast-growing neurovascular interventional devices innovative platform enterprise start-up with global HQ in Singapore. HeMo provides holistic solutions for neuro intervention: Including ischemic stroke, hemorrhagic stroke and neuro access products etc. The Singapore office is strategized to employ more than 300 engineers, corporate service and sales professionals over the course of the following three years. HeMo also has a strong presence in China, with manufacturing facilities in Weihai in Shandong Province and sales office in Beijing. HeMo is also strategically venturing into peripheral interventional products. HeMo‘s founder & management team have strong R&D, senior management, sales and operation experience across various medical devices MNCs, including Johnson & Johnson, Abbott, Boston Scientific, Novartis, Sanofi, JW Medical Systems and Biosensors International. The clinical and marketing teams have rich industry experience and successful track record of important medical device product commercialization. Unlike a typical start-up, HeMo starting point is successfully armed with proven technology and solid financial backing. HeMo’s key investors include heavyweight funds Legend Capital, 3H Health, Hillhouse Capital, Delos Capital, with corporate strategical development plans led by international renowned banks including Morgan Stanley, Credit Suisse and CICC. With existing robust pipelines of products and more mechanical solutions from organic and M&A for human veins and arteries coming up, HeMo is well positioned to become a global leading vascular interventional devices platform company in the near future.